Fortis Healthcare Q3 FY26: Revenue up 17.5% to ₹2,265 Cr, EBITDA surges 34.8%
Fortis Healthcare reported Q3 FY26 consolidated revenue of ₹2,265 Cr, up 17.5%. EBITDA grew 34.8% to ₹505 Cr, with margins at 22.3%. The company acquired People Tree Hospital in Bengaluru for ₹430 Cr and launched Adayu mental health facility. Agilus Diagnostics revenue rose 8.3% to ₹371 Cr with EBITDA at ₹86 Cr.
The announcement includes robust financial performance with significant growth in revenue and profitability, alongside strategic acquisitions and capacity expansions. These factors are material and are expected to have a substantial impact on the company's future performance and market position.
The company reported strong double-digit growth in revenue and significant improvement in EBITDA and margins for both the hospital and diagnostics segments. Strategic acquisitions and expansions were also highlighted, indicating a positive growth outlook.
Fortis Healthcare Limited announced its Un-audited Financial Results for the quarter and period ended December 31, 2025. The company reported consolidated revenues of ₹2,265 crore, a 17.5% increase over the corresponding previous period. The hospital business revenues grew by 19.4% to ₹1,938 crore, while the diagnostics business reported a revenue growth of 7.3% to ₹327 crore.
Consolidated operating EBITDA increased by 34.8% to ₹505 crore, resulting in an EBITDA margin of 22.3% in Q3 FY26, up from 19.4% in Q3 FY25. Hospital business operating EBITDA margins improved to 21.7% from 20%. Consolidated profit before tax before exceptional items rose by 21.9% to ₹312 crore. Reported PAT stood at ₹197 crore, a decrease from ₹250 crore in Q3 FY25, primarily due to a one-off expense of ₹55 crore related to New Labour Codes, offset by an impairment reversal of ₹9 crore, resulting in a net exceptional loss of ₹46 crore.
For the nine-month period of FY26, consolidated revenue stood at ₹6,763 crore, a 17.1% growth. Operating EBITDA increased to ₹1,553 crore, a 300 basis point improvement to 23% compared to the corresponding previous period. The hospital business revenue for the nine months grew 19.1% to ₹5,749 crore, with operating margins improving from 20% to 22.2%.
Fortis Healthcare also announced strategic acquisitions and expansions. In January 2026, the company acquired the 125-bedded People Tree Hospital in Bengaluru for ₹430 crore, with plans to expand it to over 300 beds. In November 2025, it launched Adayu, a 36-bedded specialized mental health care facility in Gurugram. The company has added approximately 750 operational beds year-to-date.
The diagnostics business, Agilus Diagnostics, reported gross revenues of ₹371 crore for Q3 FY26, an 8.3% year-on-year growth. Operating EBITDA stood at ₹86 crore, with margins at 23.1% compared to 14.4% in Q3 FY25. Agilus conducted 9.9 million tests during the quarter, a 3.6% volume growth.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.